Free Trial
NASDAQ:INCY

Incyte (INCY) Stock Price, News & Analysis

Incyte logo
$68.84 +1.78 (+2.65%)
(As of 12/20/2024 05:31 PM ET)

About Incyte Stock (NASDAQ:INCY)

Key Stats

Today's Range
$66.89
$69.11
50-Day Range
$65.07
$83.38
52-Week Range
$50.35
$83.95
Volume
6.77 million shs
Average Volume
2.35 million shs
Market Capitalization
$13.26 billion
P/E Ratio
491.75
Dividend Yield
N/A
Price Target
$76.29
Consensus Rating
Hold

Company Overview

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Incyte Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
94th Percentile Overall Score

INCY MarketRank™: 

Incyte scored higher than 94% of companies evaluated by MarketBeat, and ranked 61st out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Incyte has received a consensus rating of Hold. The company's average rating score is 2.35, and is based on 8 buy ratings, 11 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Incyte has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Incyte's stock forecast and price target.
  • Earnings Growth

    Earnings for Incyte are expected to grow by 1,197.50% in the coming year, from $0.40 to $5.19 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Incyte is 491.75, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 112.74.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Incyte is 491.75, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 87.03.

  • Price to Earnings Growth Ratio

    Incyte has a PEG Ratio of 8.36. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Incyte has a P/B Ratio of 2.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    3.16% of the float of Incyte has been sold short.
  • Short Interest Ratio / Days to Cover

    Incyte has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Incyte has recently decreased by 14.43%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Incyte does not currently pay a dividend.

  • Dividend Growth

    Incyte does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.16% of the float of Incyte has been sold short.
  • Short Interest Ratio / Days to Cover

    Incyte has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Incyte has recently decreased by 14.43%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Incyte has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for Incyte this week, compared to 11 articles on an average week.
  • Search Interest

    Only 2 people have searched for INCY on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • MarketBeat Follows

    10 people have added Incyte to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Incyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $839,711.00 in company stock.

  • Percentage Held by Insiders

    17.60% of the stock of Incyte is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    96.97% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Incyte's insider trading history.
Receive INCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.

INCY Stock News Headlines

Incyte Co. (NASDAQ:INCY) EVP Sells $455,521.34 in Stock
We recommended Palantir in 2021, now we’re recommending this...
My research indicates there is only one investment that can meet AI's unprecedented demand for energy.
The Analyst Verdict: Incyte In The Eyes Of 15 Experts
Incyte price target raised to $70 from $68 at Wells Fargo
Incyte's (INCY) Outperform Rating Reaffirmed at William Blair
See More Headlines

INCY Stock Analysis - Frequently Asked Questions

Incyte's stock was trading at $62.79 on January 1st, 2024. Since then, INCY stock has increased by 9.6% and is now trading at $68.84.
View the best growth stocks for 2024 here
.

Incyte Co. (NASDAQ:INCY) issued its quarterly earnings results on Tuesday, October, 29th. The biopharmaceutical company reported $1.07 EPS for the quarter, missing analysts' consensus estimates of $1.19 by $0.12. Incyte's revenue for the quarter was up 23.8% compared to the same quarter last year.
Read the conference call transcript
.

Incyte's top institutional shareholders include Baker BROS. Advisors LP (15.96%), State Street Corp (5.48%), Geode Capital Management LLC (2.04%) and Point72 Asset Management L.P. (1.23%). Insiders that own company stock include Steven H Stein, Maria E Pasquale, Barry P Flannelly, Jonathan Elliott Dickinson, Vijay K Iyengar, Thomas Tray, Bros Advisors Lp Baker, Wendy L Dixon and Paula J Swain.
View institutional ownership trends
.

Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Incyte investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST).

Company Calendar

Last Earnings
10/29/2024
Today
12/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:INCY
CUSIP
45337C10
Employees
2,524
Year Founded
1991

Price Target and Rating

Average Stock Price Target
$76.29
High Stock Price Target
$97.00
Low Stock Price Target
$52.00
Potential Upside/Downside
+10.8%
Consensus Rating
Hold
Rating Score (0-4)
2.35
Research Coverage
20 Analysts

Profitability

Net Income
$597.60 million
Pretax Margin
6.72%

Debt

Sales & Book Value

Annual Sales
$4.08 billion
Cash Flow
$2.31 per share
Book Value
$23.16 per share

Miscellaneous

Free Float
158,744,000
Market Cap
$13.26 billion
Optionable
Optionable
Beta
0.69

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:INCY) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners